Last reviewed · How we verify

NCT05158010: ATHLETE

Advancing Tools for Human Early Lifecourse Exposome Research and Translation- Adolescence Follow-up of the HELIX Subcohort

Completed NA Last updated 1 July 2022
What this trial tests

NA trial testing HELIX's follow-up in Exposure in 80 participants. Completed in 25 June 2022.

Timeline
10 November 2021
Primary endpoint
25 June 2022
25 June 2022

Quick facts

Lead sponsorPoitiers University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment80
Start date10 November 2021
Primary completion25 June 2022
Estimated completion25 June 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

Adults 16 to 18, any sex, with Exposure or Health Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ATHLETE will set up a prospective Europe-wide exposome cohort covering the first 2 decades of the life course, which will integrate data on the external, chemical, physical,behavioral, and social domains of the exposome, as well as on health outcomes and biological omics responses, from preconception until adolescence. As part of ATHLETE, the investigators will follow up a unique existing exposome cohort into adolescence (the HELIX Subcohort).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Exposure

Currently open trials in the same condition.

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05158010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing